Arcturus Therapeutics
ARCT
145 hedge funds and large institutions have $643M invested in Arcturus Therapeutics in 2023 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 50 increasing their positions, 52 reducing their positions, and 19 closing their positions.
16% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 19
5.44% more ownership
Funds ownership: 88.98% → 94.42% (+5.4%)
1% more funds holding
Funds holding: 143 → 145 (+2)
4% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 52
5% less capital invested
Capital invested by funds: $678M → $643M (-$34.5M)
13% less call options, than puts
Call options by funds: $6.3M | Put options by funds: $7.24M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$12.3M |
| 2 |
Morgan Stanley
New York
|
+$11.3M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10.2M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$8.59M |
| 5 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$8.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$9.74M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.83M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$4.39M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.79M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$3.65M |
ARCT Hedge Fund Activity: Q3 2023 in Review
145 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q3 2023, worth a combined $643M — down 5.1% from $678M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ARCT positions and 19 closed out — a net gain of 3 holders — while 50 added to existing stakes and 52 trimmed.
The largest buyer was Granahan Investment Management, opening a new position worth an estimated $12.3M. The largest seller was State Street, cutting an estimated $9.74M.
- 145 institutional investors held Arcturus Therapeutics (ARCT) as of Q3 2023, up from 143 in Q2 2023.
- Funds reported $643M of Arcturus Therapeutics stock for Q3 2023, down 5.1% quarter-over-quarter.
- 22 funds opened new Arcturus Therapeutics positions in Q3 2023 and 19 closed out, a net change of +3 holders.
- The largest Arcturus Therapeutics buyer in Q3 2023 was Granahan Investment Management, an estimated $12.3M added.
- The largest Arcturus Therapeutics seller in Q3 2023 was State Street, an estimated $9.74M sold.
Based on aggregated 13F filings for Q3 2023.